Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG)

Mohamad Abou Chakra; Igor Duquesne; Michael Peyromaure; Sarah L Mott; Mohamad Moussa; Michael A O'Donnell

doi:10.1080/14656566.2024.2323609

Back

Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG)

Journal article

Peer reviewed

Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG)

Mohamad Abou Chakra, Igor Duquesne, Michael Peyromaure, Sarah L Mott, Mohamad Moussa and Michael A O'Donnell

Expert opinion on pharmacotherapy, Vol.25(3), pp.315-324

02/11/2024

DOI: 10.1080/14656566.2024.2323609

PMID: 38393775

View Online

Abstract

To evaluate the impact of having first-degree relatives (FDR) with bladder cancer (BC) among non-muscle invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette - Guérin (BCG) on their oncological outcomes. The National Phase II BCG/Interferon (IFN) trial database from 125 sites in the U.S.A. (1999-2001) and multi-institutional databases from France (FR) and Lebanon (LB) (2000-2021) were queried for NMIBC patients treated with BCG. Cox regression models were used to evaluate the effect of BC family history on tumor recurrence and progression in their relatives. There were 867 patients in the U.S.A. cohort and 1232 patients in the FR/LB cohort. Almost 8% of patients in both cohorts had FDR with BC. Patients in the FR/LB cohort were more likely to have carcinoma in situ tumors (CIS) (41% vs. 24%, < 0.01). Having FDR with BC was not significantly associated with tumor recurrence or progression in the U.S.A. cohort. Conversely, it was significantly associated with a 2.10 times increased risk of recurrence ( < 0.01) and a 3.01 times increased risk of progression ( < 0.01) in the FR/LB cohort on multivariable analysis. A family history of BC could have an important impact on the response to BCG.

oncological outcome

family history

BCG

non-muscle invasive bladder cancer

Details

Title: Subtitle: Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG)
Creators: Mohamad Abou Chakra - Department of Urology, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA
Igor Duquesne - Hôpital Cochin
Michael Peyromaure - Hôpital Cochin
Sarah L Mott - University of Iowa
Mohamad Moussa - Lebanese University
Michael A O'Donnell - University of Iowa
Resource Type: Journal article
Publication Details: Expert opinion on pharmacotherapy, Vol.25(3), pp.315-324
DOI: 10.1080/14656566.2024.2323609
PMID: 38393775
eISSN: 1744-7666
Language: English
Electronic publication date: 02/23/2024
Date published: 02/11/2024
Academic Unit: Urology
Record Identifier: 9984560420502771

Metrics

10 Record Views